Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy
Advanced Science · 2024-02 · 11 (5)
DOI: 10.1002/advs.202303088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.11.2023. Verfasst von Daheui Choi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, 55905, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NIDDK NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Patient‐derived cancer organoids (PDOs) hold considerable promise for personalizing therapy selection and improving patient outcomes. However, it is challenging to generate PDOs in sufficient numbers to test therapies in standard culture platforms. This challenge is particularly acute for pancreatic ductal adenocarcinoma (PDAC) where most patients are diagnosed at an advanced stage with non‐resectable tumors and where patient tissue is in the form of needle biopsies. Here the development and characterization of microfluidic devices for testing therapies using a limited amount of tissue or PDOs available from PDAC biopsies is described. It is demonstrated that microfluidic PDOs are phenotypically and genotypically similar to the gold‐standard Matrigel organoids with the advantages of 1) spheroid uniformity, 2) minimal cell number requirement, and 3) not relying on Matrigel. The utility of microfluidic PDOs is proven by testing PDO responses to several chemotherapies, including an inhibitor of glycogen synthase kinase (GSKI). In addition, microfluidic organoid cultures are used to test effectiveness of immunotherapy comprised of NK cells in combination with a novel biologic. In summary, our microfluidic device offers considerable benefits for personalizing oncology based on cancer biopsies and may, in the future, be developed into a companion diagnostic for chemotherapy or immunotherapy treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, 55905, USA.
- Division of Experimental Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
- Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, 55905, USA.
- Division of Oncology Research, College of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
- Department of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.
- Division of Medical Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
ORCID-Profile: Alan M Gonzalez-Suarez, Alexander Revzin
Förderung
- NIH HHS
- NCI NIH HHS
- NIDDK NIH HHS
- NIGMS NIH HHS
- NHLBI NIH HHS
- National Institutes of Health
- Mayo Clinic
Zitieren
APA
Choi, D., Gonzalez-Suarez, A. M., Dumbrava, M. G., Medlyn, M., de Hoyos-Vega, J. M., Cichocki, F., Miller, J. S., Ding, L., Zhu, M., Stybayeva, G., Gaspar-Maia, A., Billadeau, D. D., Ma, W. W., & Revzin, A. (2024). Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy. Advanced Science, 11(5). https://doi.org/10.1002/advs.202303088
Vancouver
Choi D, Gonzalez-Suarez AM, Dumbrava MG, Medlyn M, de Hoyos-Vega JM, Cichocki F, et al. Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy. Advanced Science. 2024;11(5). doi:10.1002/advs.202303088
BibTeX
@article{Choi2024,
author = {Choi, Daheui and Gonzalez-Suarez, Alan M and Dumbrava, Mihai G and Medlyn, Michael and de Hoyos-Vega, Jose M and Cichocki, Frank and Miller, Jeffrey S and Ding, Li and Zhu, Mojun and Stybayeva, Gulnaz and Gaspar-Maia, Alexandre and Billadeau, Daniel D and Ma, Wen Wee and Revzin, Alexander},
title = {Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {5},
doi = {10.1002/advs.202303088}
}
EUVIMED